v3.26.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Schedule of Disaggregation of Revenue

The following table presents consolidated revenues by type:

 

 

Years Ended
December 31,

 

 

2025

 

 

2024

 

 

(In thousands)

 

Laboratory Services

 

$

4,031

 

 

$

1,859

 

Laboratory Developed Test Services

 

 

 

 

 

22

 

Kitted Products

 

 

24

 

 

 

 

Total

 

$

4,055

 

 

$

1,881

 

Schedule of Concentration of Risk

The following table presents the percentage of consolidated revenues by type:

 

 

Years Ended
December 31,

 

 

2025

 

 

2024

 

Laboratory Services

 

 

99

%

 

 

99

%

Laboratory Developed Test Services

 

 

0

%

 

 

1

%

Kitted Products

 

 

1

%

 

 

0

%

Total

 

 

100

%

 

 

100

%

Schedule of Consolidated Revenues Generated by Unaffiliated Customers

The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:

 

 

Years Ended
December 31,

 

 

2025

 

 

2024

 

Company A

 

 

99

%

 

 

84

%

Company B

 

*

 

 

*

 

 

* Less than 10%

Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations

The following table presents the percentage of consolidated revenues attributable to geographical locations, based on country of domicile:

 

 

Years Ended
December 31,

 

 

2025

 

 

2024

 

United States

 

 

99

%

 

 

89

%

Outside of the United States

 

 

1

%

 

 

11

%

Total

 

 

100

%

 

 

100

%

Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock

For the years ended December 31, 2025 and 2024, all common stock equivalents are antidilutive because iMDx reported a net loss. The following table presents the calculation of basic and diluted loss per share of common stock:

 

 

Years Ended
December 31,

 

 

2025

 

 

2024

 

 

(In thousands, except per share data)

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(50,222

)

 

$

(60,663

)

Accretion of Series A redeemable convertible preferred stock

 

 

 

 

 

(263

)

Net loss attributable to common stockholders - basic and diluted

 

$

(50,222

)

 

$

(60,926

)

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

Weighted average shares outstanding - basic and diluted

 

 

30,476

 

 

 

13,071

 

 

 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

 

Net loss attributable to common stockholders per share - basic and diluted

 

$

(1.65

)

 

$

(4.66

)

 

 

 

 

 

 

 

Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:

 

 

 

 

 

 

Stock options

 

 

2,251

 

 

 

1,091

 

RSUs

 

 

852

 

 

 

100

 

Warrants

 

 

761

 

 

 

761

 

Total

 

 

3,864

 

 

 

1,952